Vogel, Adam P. http://orcid.org/0000-0002-3505-2631
Rommel, Natalie
Oettinger, Andreas
Stoll, Lisa H.
Kraus, Eva-Maria
Gagnon, Cynthia
Horger, Marius
Krumm, Patrick
Timmann, Dagmar
Storey, Elsdon
Schöls, Ludger
Synofzik, Matthis
Funding for this research was provided by:
Ataxia Charlevoix-Saguenay Foundation
H2020 Excellent Science (643578)
BMBF (01GM1607)
E-Rare-3
National Health and Medical Research Council (1082910)
Article History
Received: 15 January 2018
Revised: 18 June 2018
Accepted: 20 June 2018
First Online: 2 July 2018
Compliance with ethical standards
:
: Prof. Timmann receives funding from the German Research Foundation (DFG), the Mercator Research Center Ruhr and the German Heredoataxia Foundation unrelated to this study. Prof. Storey receives funding from the NIH, unrelated to this study. Prof. Dr. Schöls receives funding from the German Research Foundation (DFG), the European Union and the German Hereditary Spastic Paraplegia Foundation unrelated to this study. Dr. Synofzik received honoraria from Actelion pharmaceuticals, unrelated to the current study.
: The study received institutional approval from the Medical Ethics Board, University Hospital Tübingen, Germany (Az. 003/2015BO2) and The University of Melbourne Human Research Ethics Committee. All patients, or representatives, provided written informed consent. The project was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.